April 13, 2024

Researchers Harness Probiotic Bacteria To Deliver Parkinson’s Disease Treatment

” We are harnessing the metabolic capability of beneficial microorganisms that live in the gut to manufacture a molecule that is the gold standard restorative technique for Parkinsons illness,” stated Anumantha Kanthasamy, PhD, professor and Johnny Isakson Chair, Georgia Research Alliance Eminent Scholar at the University of Georgia (UGA) in Athens, Ga. “This next-generation microbial bioengineering technology is designed so that Parkinsons clients could make their own L-DOPA with microorganisms in their gut.”
Piyush Padhi, a doctoral student in Kanthasamys lab, provided the brand-new research study at the American Society for Pharmacology and Experimental Therapeutics annual meeting throughout the Experimental Biology (EB) 2022 conference, which was hung on April 2-5, 2022, in Philadelphia.
A probiotic was crafted to endogenously produce L-DOPA from tyrosine utilizing recombinant 4-hydrophenylacetate 3-monooxygenase and FAD reductase genes. The L-DOPA live-biotherapeutic is pre-activated and orally administered. Tests of the brand-new drug delivery approach reveal steady-state plasma L-DOPA levels and brain dopamine levels in pre-clinical animal designs. Credit: Piyush Padhi, University of Georgia
Dopamine replacement in the type of levodopa L-DOPA tablets taken 3-4 times a day has actually been used to treat Parkinsons disease for over 6 years. While the treatment does minimize disease signs, serious motor negative effects– described as levodopa-induced dyskinesia– start to establish after about five years of usage. This complication is linked to the fact that delivery of L-DOPA to the brain isnt continuous.
To address this challenge, Kanthasamys research study group utilized recently developed artificial biology and hereditary engineering techniques to create a safe and tolerable probiotic germs that can synthesize L-DOPA from tyrosine produced by the body.
” After numerous iterations and enhancing gut microbiome-based drug shipment technology, we have established a gut-healthy probiotic germs that can produce stable levels of L-DOPA in a method that can be highly tuned to deliver the dosage needed for each patient,” stated Padhi.
Ideally, the treatment would be provided in an encapsulated pill taken when or twice a day. The dosage can be changed by pre-activating the cells with rhamnose– an easy sugar that enables the bacteria to produce L-DOPA– or customizing the variety of bacteria cells provided in a pill.
Tests of the brand-new drug delivery technique in rodent and canine designs revealed that it can attain consistent L-DOPA levels in blood plasma and consistent brain dopamine levels with no undesirable change. The scientists likewise found that the live biotherapeutic enhanced motor, cognitive and mood-related tasks in a mouse design of Parkinsons illness.
” We are hoping that our continuous, non-pulsatile microbial-based shipment method for L-DOPA restricts the advancement and development of levodopa-induced dyskinesia,” stated Kanthasamy, who likewise directs UGAs Center of Brain Science and Neurodegenerative Disease. “We are presently exploring utilizing this technique to provide treatments for other conditions such as Alzheimers illness and anxiety and are in process of starting FDA approval for scientific testing of this unique gut microbiome therapeutic technology.”
Piyush Padhi will provide this research from 10 a.m.– 12 p.m., Sunday, April 3, in Exhibit/Poster Hall A-B, Pennsylvania Convention Center (Poster Board Number B182) (abstract) and 1:31– 1:44 p.m., Monday, April 4, in Room 109 AB (abstract). This work will be featured in a virtual interview from 11– 11:45 a.m. EDT on Friday, April 1 (RSVP by Thursday, March 31). Contact the media team to learn more or to obtain a free press pass to go to the conference.
Fulfilling: Experimental Biology 2022

A probiotic was engineered to endogenously produce L-DOPA from tyrosine using recombinant 4-hydrophenylacetate 3-monooxygenase and FAD reductase genes. The L-DOPA live-biotherapeutic is pre-activated and orally administered. Tests of the brand-new drug shipment method expose steady-state plasma L-DOPA levels and brain dopamine levels in pre-clinical animal models. Dopamine replacement in the type of levodopa L-DOPA tablets taken 3-4 times a day has been used to deal with Parkinsons illness for over 6 years.

Animal studies reveal live biotherapeutic produced by gut-healthy probiotic germs is safe, reduces treatment problems.
Scientists have crafted probiotic germs that can synthesize the dopamine precursor L-DOPA, an effective essential treatment for Parkinsons disease. Preclinical tests show that the new treatment approach is not just safe and well-tolerated however also eliminates side impacts that ultimately establish when L-DOPA is taken orally.